Active Substance: Asparaginase.
Overview
Welcome to Dwaey, specifically on SPECTRILA 10000 U page.
This medicine contains an important and useful components, as it consists of
Asparaginaseis available in the market in concentration
L-Asparaginase
Should be used after skin testing, in hospital setting. Liver disease, frequently blood count monitoring. Lactation. Lactation: It is not known whether this drug is excreted in milk. Because of the potential for serious adverse reactions in nursing infants from Elspar, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Acute Lymphocytic Leukemia
Hypersensitivity. History of pancreatitis, thrombosis, or serious pancreatitis events with prior L-asparaginase treatment.
>10% Abdominal cramps (70%),Anorexia (70%),Azotemia (66%),Nausea (50-60%),Vomiting (50-60%),Agitation (10-60%),Depression (10-60%),Fatigue (10-60%),Fever (10-60%),Chills (10-60%),Anaphylaxis (15-35%),Coma (25%),Confusion (25%),Somnolence (25%),Stupor (25%),Pancreatitis, acute (15%) 1-10% Hyperglycemia,Stomatitis,Hyperuricemia <1% Disorientation,Drowsiness,Hallucination,Headache,Hyperthermia,Parkinsonian symptoms,Venous thrombosis,Hypotension,Intracranial hemorrhage,Cerebrovascular hemorrhage,Peripheral edema,Thrombosis,Cough,Hypofibrinogenemia,Depression of clotting factors,Severe protein C deficiency,Decrease antithrombin III,Glucosuria,Hemorrhagic pancreatitis,Ketoacidosis,Hepatotoxicity,Urticaria,Weight loss,Acute renal failure
3
Asparaginase interferes with malignant cell growth by breaking down asparagine to aspartic acid and ammonia as leukemic cells are unable to synthesise asparagine and depends on exogenous source of asparagine for survival. It acts on the G1 phase of the cell cycle.
Activity of methotrexate may be reduced if L-asparaginase is given before hand. Potentially Fatal: IV admin of asparaginase may increase vincristine neurotoxicity.
Information not available